Predicting the presence or absence of ringed sideroblasts in patients suspected of having a myelodysplastic syndrome and increased iron stores: a simple observation TO 
THE EDITOR
Refractory anemia with ringed sideroblasts (RARS) is one of the various myelodysplastic syndromes. It is characterized by 15% or more ringed sideroblasts in the bone marrow, 1 increased bone marrow iron stores 2 and less than 5% blasts in the bone marrow or less than 1% blasts in the peripheral blood. 3 Ringed sideroblasts are erythroid precursors that have perinuclear aggregates of iron-laden mitochondria. 4 Iron stores and ringed sideroblasts are demonstrated by staining the bone marrow smears with an acid potassium ferrocyanide solution (Prussian blue). 5 Increased hemosiderin deposits are commonly seen in chronically transfused patients for various reasons including chemotherapy induced anemia. 6 Myelodysplastic syndromes quite frequently have increased bone marrow iron stores. 7 Increased iron deposits in patients with RARS have been described as finely granular or rarely coarsely granular. 8 In hemosiderosis due to chronic transfusions the intracytoplasmic iron granules are large. 2 We have observed that specific patterns of iron distribution are associated with the presence or absence of ringed sideroblasts ascertained with low power (4×-10×) light microscopy.
Prussian blue-stained bone marrow aspirate smears were reviewed from 58 adult and pediatric patients reported to have increased iron stores from 1993 to 2000 at Geisinger Medical Center in the Department of Laboratory Medicine. Twenty-seven patients were identified as having RARS. Thirty-one patients were chosen as controls on the basis of having increased bone marrow stores and a diagnosis other than RARS. The first bone marrow examination in patients with the diagnosis of RARS was used since the majority of these patients had multiple bone marrow examinations after the diagnosis was made and the iron staining pattern can change over time. The control group included various diagnoses such as acute myelogenous leukemia, acute lymphoblastic leukemia, Hodgkin's and non-Hodgkin's lymphoma, end-stage renal disease, reactive marrow, chronic lymphocytic leukemia, metastatic small cell carcinoma, immune thrombocytopenic purpura, essential thrombocytemia, monoclonal gammopathy of unknown significance and a normal marrow. Many of these patients had been chronically transfused and received chemotherapy for their respective malignancies. In cases where more than one smear was discovered for a single patient, the chronologically first smear was used for inclusion in the study. Laboratory computer records were reviewed to identify which patients had been multiply transfused. Geisinger Medical Center's Institution Research Review Board approved the study. The iron-stained slides were randomly arranged in trays and independently reviewed by two observers (RPD and MA) with no knowledge of the previous diagnoses. The investigators classified the morphologic pattern of each case on low power light microscopy into three categories: a diffuse pattern, a punctate pattern and a mixed pattern. Few inter-observer discrepancies were encountered. These mostly occurred with the mixed pattern and were reviewed simultaneously by both microscopists to reach a consensus. A diffuse pattern was defined as that in which the hemosiderin deposits are finely granular and diffusely distributed throughout the marrow particles appearing as a hazy bluish stain over the fat globules ( Figure 1 ). A punctate pattern was defined as that in which coarse granular iron deposits are heavily concentrated in and around macrophages in the particles. The focal distribution of iron within histiocytes gives it the punctate appearance and leaves the other marrow elements in the particle clearly visible ( Figure 2 ). A mixed pattern was defined as a hybrid between the diffuse and punctate patterns.
After classifying the patients by morphologic pattern, data analyses were conducted to determine if the presence or absence of ringed sideroblasts could be predicted by low power examination of the ironstained marrow aspirate slide. The chi-square test or the Fisher's exact test (in cases of small samples) was used to test for differences in prevalence of a punctate morphologic pattern. SAS 8.01 (Statistical Analysis Systems, Cary, NC, USA) was used for all data manipulations and analyses.
A total of 58 different patients' bone marrow aspirate iron stains with increased hemosiderin deposits were reviewed. Twenty-seven patients had the diagnosis of RARS. Thirty-one patients did not have the diagnosis of RARS and were thus identified as the control group (see Table 1 ).
Of the 27 patients with the diagnosis of RARS, none (0%) had a pure punctate pattern. All 27 (100%) of the patients with RARS had a diffuse pattern originally (26 with pure diffuse and one with a mixed diffuse and punctate pattern). In the 31 control patients, 13 (42%) had a pure punctate pattern, 15 (48%) had a diffuse pattern and three (10%) had a mixed pattern. Thus, patients with a diagnosis of RARS were more likely to have a diffuse pattern at the time they are first
Figure 1
Bone marrow aspirate iron stain with a diffuse pattern. Original magnification ×10, top; ×25 bottom. diagnosed (100% vs 58% (chi-square = 14.6, P Ͻ 0.001)) than the control group.
Several of the control patients (n = 21; 68%) had been chronically transfused for various reasons including anemia induced by chemotherapy for hematologic or non-hematologic malignancies or endstage renal disease. This can explain the iron overload observed in this group. There was one patient with RARS that had a mixed diffuse and punctate pattern. Upon further investigation, this patient had been multiply transfused before the bone marrow examination. In five patients, the first bone marrow iron stain had a diffuse pattern. Latter bone marrow examinations had a mixed diffuse and punctate pattern. In five patients there was a record of multiple transfusions either after or close to the time of the original bone marrow examination. No transfusion record was found on one patient. Thus, multiple transfusions and their subsequent iron overload may lead to a punctate pattern.
Every bone marrow iron stain should be evaluated under oil immersion to determine the presence or absence of ringed sideroblasts. However, before using the oil objective, the observer may predict with certain accuracy if many ringed sideroblasts will be found by noting if there is an increase in iron stores and by determining the type of pattern the iron deposits have on low power (4×-10× objectives) light microscopy. A diffuse pattern is more likely to have many ringed sideroblasts. Conversely, ringed sideroblasts are more likely to be absent if a punctate pattern is found. If a mixed pattern is noted, then the patient has probably received numerous blood transfusions and predicting the presence or absence of ringed sideroblasts is not feasible.
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Figure 2
Bone marrow aspirate iron stain with a punctate pattern. Original magnification ×10, top; ×25 bottom. 
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571
TO THE EDITOR Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder arising from a neoplastic transformation in a stem cell capable of differentiating into myeloid, erythroid, megakaryocytic, B-lymphoid and occasionally T-lymphoid cell lineages. The hallmark of the disease is the Philadelphia (Ph) chromosome formed from a reciprocal translocation t(9;22)(q34;q11), found in up to 95% of the cases. Here we report a patient who was enrolled on multinational trial of STI571 in interferon-resistant patients and 3 months later developed triploidy, as well as amplification of the BCR-ABL gene. The patient was a 60-year-old woman who was diagnosed with Ph-positive CML in 1995. At that time, her white cell count (WBC) was 25 000/mm 3 with hemoglobin of 12.7 g/dl, a hematocrit of 38% and platelets of 300 000/mm 3 . Initially she was treated with interferon alpha for 1 year. Although she remained stable during that time and her WBC counts decreased, she did not show a cytogenetic response. In 1997, Ara-C was added to her treatment regimen with no significant response. In June 2000, the patient was enrolled in an STI571 clinical trial (dose of 400 mg/day) when she showed evidence of disease progression manifested by an enlarging spleen, WBC count of 51 000/mm 3 , anemia and thrombocytopenia. A bone marrow biopsy and aspirate performed prior to enrollment in the study were consistent with chronic phase CML. Cytogenetics studies showed 46,XX,t(9;22)(q34;q11.2). Interphase FISH analysis with BCR-ABL ES (extra sensitive) probe (Vysis, Downers Grove, IL, USA) showed that 91% of her cells were positive for the BCR-ABL fusion gene.
Despite STI571 treatment and decrease of WBC count to 3400/mm 3 over 3 months, the patient's condition worsened manifesting increased anemia and thrombocytopenia which required frequent transfusions. In addition, more than 10% of her circulating WBC were blasts. In October 2000, at the time of her first interval follow-up while on STI571, cytogenetic analysis was performed on 32 bone marrow metaphases. It showed the modal karyotype 69-72,XXX, +1, +der(4)t(4;?)(q36;?), +6, −7, +8, +8, t(8;17)(q23;q22), t(9;22)(q34;q11. acentric fragments (Figure 1 ). There were two copies of der(9) and no normal chromosome 9. Each cell had either four copies of the Ph chromosome or three copies of the Ph chromosome and one copy of ider (22) Figure  2 ). Metaphase FISH analysis confirmed the lack of normal chromosome 9 and 22. Further, metaphase FISH using chromosome painting probes confirmed pentasomy of chromosome 8, tetrasomy for chromosome 14, t(8;17) and the additional deleted chromosome 17. By the end of October 2000, the patient was hospitalized because of severe pneumonia complicated with sepsis and expired soon after hospitalization.
To our knowledge, this is the first report that describes homozygous Ph chromosome that developed at two different time points; at diagnosis and 3 months following induction of ST1571 therapy. The most likely explanation is that the second translocation t(9;22) and the amplification of each Ph chromosome were related to ST1571 treatment. It is possible however, that these genetic alterations are a manifestation of transformation of chronic phase CML into blast crisis; however, neither these findings nor the triploidy are characteristic of such an event. Blast crisis of CML may be myeloid or lymphoid. About 15-20% of patients in blast crisis retain the 46 Ph + cell population unchanged, whereas 80-85% show karyotypic evolution. The most common changes, gain of chromosomes 8, 19 and i(17q) frequently occur in combination with duplication of the Ph chromosome to produce modal chromosome numbers of 47-50. When patients have only a single new chromosome change, it most commonly, involves the gain of the second Ph, an i(17q), or +8, or +19 in descending order of frequency. Other rearrangements occur less frequently. The chromosome 22 homologue is almost always intact. To our knowledge, blast crisis characterized by a triploid range of chromosomes has not been reported. Triploidy in this patient, combined with pentasomy 8, is another unique aspect, and may represent either a rare cytogenetic evolution in blast crisis or it may be related to ST1571 treatment. One could speculate that cell resistance to ST1571 may be caused by deregulation of protein kinases genes involved in cell cycle checkpoints resulting in increased ploidy.
In ongoing phase I clinical trials, ST1571 showed significant activity in all phases of CML, as well as Ph chromosome-positive acute leukemias. 3, 4 At daily oral doses of 300 mg or more, a complete hematological response was achieved in 100% of the patients in chronic phase CML and cytogenetic responses were observed in 53% with complete cytogenetic remissions in 13%. Most of these responses are maintained with ongoing therapy. In patients with Ph-positive acute leukemias, relapses have been a major problem. This raises the possibility that later relapses will also be seen in chronic phase patients because of resistance to ST1571.
Experiments in mouse and human cell lines have shown that the most frequent mechanism of resistance to standard doses of ST1571 is amplification and overexpression of the BCR-ABL gene. 5 Similar to
